KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other financing activities (2016 - 2023)

Ionis Pharmaceuticals has reported Other financing activities over the past 9 years, most recently at -$14.2 million for Q4 2023.

  • Quarterly results put Other financing activities at -$14.2 million for Q4 2023, down 2025.95% from a year ago — trailing twelve months through Dec 2024 was -$13.7 million (down 11.24% YoY), and the annual figure for FY2022 was $11.0 million, down 34.51%.
  • Other financing activities for Q4 2023 was -$14.2 million at Ionis Pharmaceuticals, down from $517000.0 in the prior quarter.
  • Over the last five years, Other financing activities for IONS hit a ceiling of $15.3 million in Q1 2021 and a floor of -$14.2 million in Q4 2023.
  • Median Other financing activities over the past 5 years was $503500.0 (2021), compared with a mean of $1.8 million.
  • Biggest five-year swings in Other financing activities: soared 1584.48% in 2019 and later tumbled 3331.92% in 2020.
  • Ionis Pharmaceuticals' Other financing activities stood at $401000.0 in 2019, then tumbled by 3331.92% to -$13.0 million in 2020, then soared by 103.4% to $440000.0 in 2021, then skyrocketed by 67.27% to $736000.0 in 2022, then tumbled by 2025.95% to -$14.2 million in 2023.
  • The last three reported values for Other financing activities were -$14.2 million (Q4 2023), $517000.0 (Q3 2023), and $736000.0 (Q4 2022) per Business Quant data.